Cardioplegic Solutions

02/01/1996 - "In conclusion, for myocardial preservation, the addition of diltizaem to St. Thomas' cardioplegic solution was less effective for the 60 min global ischemia. "
09/01/1986 - "This study tests the hypothesis that improved muscle salvage after prolonged ischemia (4 hours) occurs when the substrate-enriched blood cardioplegic solution is markedly hyperglycemic (greater than 400 mg/dl) and markedly hyperosmotic (greater than 400 mOsm). "
03/01/1991 - "One of the methods of donor heart protection against ischemia is a substantial lowering of temperature of the heart perfused with cardioplegic solution (CS). "
01/01/2006 - "The aim of this study is to investigate whether the addition of Ptx into the cardioplegic solutions avoids myocardial inflammatory reactions and ischemia/reperfusion (I/R) injury during extracorpereal circulation. "
03/01/1995 - "The study demonstrated the advantages of combined antegrade-retrograde delivery of cardioplegic solution during ischemia in aortocoronary shunting and correction of valvular defects. "

01/01/2006 - "First, most cardiac surgery is performed under ischemic arrest induced by a cardioplegic solution, and the protective effects of ACE inhibition against reperfusion injury can reduce peri-operative mortality and morbidity. "
10/01/2008 - "Mitochondrial ischemia-reperfusion injury of the transplanted rat heart: improved protection by preservation versus cardioplegic solutions."
01/01/2007 - "Bioelectric impedancemetry allows evaluation of interstitium filling during infusion of the cardioplegic solution and reperfusion damage to cardiomyocytes."
01/01/1998 - "In contrast, addition of BDM to the cardioplegic solution provided no protection from ischemic or reperfusion injury."
12/01/1994 - "These results showed that leukocyte-depleted terminal blood cardioplegic solution may have a role in attenuating reperfusion injury in patients with critical conditions such as preoperative myocardial ischemic injury."

04/01/1987 - "Although many studies of the protective effects of cardioplegic solutions using hypothermia have been conducted, it is also necessary to examine their protective effects under normothermia as regional increases in myocardial temperature during hypothermic arrest are often reported. "
09/01/1978 - "The evidence from this study indicates that cardioplegic solution exerts a protective effect beyond that which is afforded by hypothermia."
09/01/2010 - "Influence of hypothermia and cardioplegic solutions on expression of alpha-Gal epitope on porcine aortic endothelial cells."
07/15/1996 - "This endogenous mechanism of cardioprotection was effective regardless of whether preservation was accomplished using cardioplegic solution or topical hypothermia alone. "
06/01/1994 - "The Perfusion of cardioplegic solution significantly increased [Ca2+]i, and this effect was further augmented by hypothermia (p < 0.05). "

01/01/2014 - "Infusion of high-KCl cardioplegic solution (High-KCS) is the most common method used to induce asystole before cardiac surgery. "
05/01/2012 - "During heart procurement we initially infused 1,000 mL cold St Thomas cardioplegic solution to achieve cardiac arrest. "
01/01/2012 - "Surgical technique include mitral valve repair or replacement through right lateral minithoracotomy, percutaneous cannulation for venous drainage and optional femoral or distal ascendant aortic cannulation for vacuum assisted CPB, direct cross clamping of the aorta with anterograde administration of the cardioplegic solution for inducing cardiac arrest. "
04/01/2005 - "This procedure has traditionally been "invasive", requiring a micro-surgery technique, institution of extra-corporeal circulation, as well as temporary cardiac arrest with a cardioplegic solution. "
02/01/2003 - "Cardiac arrest was induced with 4 degrees C St. Thomas cardioplegic solution, at which point the heart was made globally ischemic by withholding perfusion for 45 min followed by 40 min reperfusion. "

04/01/1993 - "In relation to the group with cardioplegic solution alone, postischemic aortic flow, coronary flow, cardiac output, and stroke work were all significantly greater (p < 0.05) in the group with the receptor antagonist (aortic flow: 49.5 +/- 2.4 versus 29.4 +/- 3.3 ml/min; coronary flow; 12.4 +/- 1.2 versus 8.5 +/- 1.3 ml/min; cardiac output, 62.0 +/- 2.8 versus 38.0 +/- 4.4 ml/min; stroke work, 12.6 +/- 0.8 versus 7.1 +/- 0.8 cm H2O.ml). "
04/01/1993 - "Within the group protected by cardioplegic solution alone, postischemic aortic flow, coronary flow, cardiac output, and stroke work were all significantly decreased (p < 0.05) compared with preischemic values (aortic flow, 50.8 +/- 2.7 versus 29.4 +/- 3.3 ml/min; coronary flow, 13.2 +/- 1.3 versus 8.5 +/- 1.3 ml/min; cardiac output, 64.0 +/- 3.8 versus 38.0 +/- 4.4 ml/min; stroke work, 12.5 +/- 0.7 versus 7.1 +/- 0.8 cm H2O.ml). "
10/01/1999 - "Compared with the protection afforded by blood cardioplegic solution without L-arginine (group 1), the addition of a 4 mmol/L concentration of L-arginine (group 2) significantly improved myocardial protection, resulting in complete return of systolic function (end-systolic elastance 38% vs 100%; P <.001 vs 4 mmol/L L-arginine) and preload recruitable stroke work (40% vs 100%; P <. "
02/01/1995 - "The results showed improved early recovery of preload recruitable stroke work area, but not of maximal elastance, after reperfusion of ischemic hearts with warm resuscitative blood cardioplegic solution enhanced with amino acids. "
10/01/1999 - "In contrast, cardioplegic solutions modified with L-arginine, prostaglandin E(1), or leukodepletion, resuscitated the stressed myocardium, resulting in complete return of systolic function (100% vs 101% vs 101%; P <.001 vs group 1) and preload recruitable stroke work (100% vs 101% vs 101%; P <.001 vs group 1), minimal increase in diastolic stiffness (160% vs 162% vs 160%; P <. "